MiniMed Group, Inc. (MMED) Stock Price & How to Invest

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company building treatments for brain-health and psychiatric disorders from psychedelic and related compounds. Its lead asset is DT120 (formerly MM120), a pharmaceutically optimized, orally disintegrating tablet form of lysergide (LSD) D-tartrate being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD). A Phase 2b study met its endpoints with durable anxiety improvement to Week 12, and the program carries FDA Breakthrough Therapy Designation for GAD, with results published in JAMA. The company also has earlier-stage programs including MM402 (an R-MDMA candidate) for autism spectrum disorder. In January 2026 the company rebranded to Definium Therapeutics and its Nasdaq ticker changed from MNMD to DFTX (the MMED symbol traced to its earlier Canadian listing).

The investment picture is a classic pre-profit biotech setup: no product revenue, large R&D-driven net losses, and a sizeable balance sheet meant to fund trials for years. As of Q1 2026 the company held roughly $373M in cash and investments, guiding a runway into 2028, and it raised about $259M in a November 2025 offering. The story now rides on three Phase 3 readouts expected in 2026 (Voyage and Panorama in GAD, Emerge in MDD). That makes the stock highly catalyst-sensitive: positive data could re-rate the shares, while a miss would leave a company valued far above its trailing fundamentals, and the market cap (several billion dollars against zero revenue) reflects expectations, not results.

The company is unprofitable and cash-burning, with a Q1 2026 net loss reported near $77M (inflated by non-cash warrant fair-value changes) on operating expenses around $59M and no product revenue, so the multi-billion-dollar market value rests entirely on future clinical and regulatory success rather than current fundamentals. The stock is highly binary: a miss on any of the 2026 Phase 3 readouts could sharply reset the valuation. Psychedelic medicines also face regulatory, scheduling, reimbursement, and clinical-delivery uncertainties (LSD is a controlled substance), plus the usual risks of trial failure and competition. While the runway extends into 2028, sustained losses and commercialization costs could eventually require dilutive financing, and shares have been highly volatile.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see MiniMed Group, Inc.'s investor relations page or your broker.

• Market cap: ~$4.7B (mid-2026)
• Product revenue: ~$0 (pre-commercial)
• Net loss (Q1 2026): ~$77M (incl. non-cash warrant charge)
• Operating expenses (Q1 2026): ~$59M (R&D ~$42M, G&A ~$18M)
• Cash & investments: ~$373M (Mar 2026)
• Cash runway: guided into 2028

Mind Medicine (Definium) has no P/E because it is pre-revenue and unprofitable, so investors typically frame it on cash-versus-market-cap and pipeline optionality: only a fraction of the several-billion-dollar market value is backed by cash, with the remainder pricing the probability-weighted outcome of the 2026 Phase 3 readouts. Revenue is zero, which is normal for a clinical-stage biotech but means the shares trade on catalysts, not fundamentals. The reported Q1 net loss was materially distorted by a non-cash change in the fair value of financing warrants tied to the share-price rise, so operating cash burn is a better gauge of spending.

There are three common ways to get MMED exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so MMED sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where MMED fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Mind Medicine (now Definium) is a well-funded but pre-profit psychedelic-medicine developer whose price hinges on 2026 Phase 3 data, so it fits only an investor comfortable with high-variance, catalyst-driven biotech risk.

Whether MMED is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MMED a buy?, and where the stock could go from here in the MMED stock forecast.

For income investors, whether MMED pays a dividend and how the payout looks is covered in does MMED pay a dividend?